Overview

A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy
Phase:
PHASE3
Details
Lead Sponsor:
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.